Congenital growth hormone deficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Congenital growth hormone deficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of the effects of Ibutamoren Mesilate in prepubertal children with growth hormone deficiency https://clinicaltrials.eu/trial/study-of-the-effects-of-ibutamoren-mesilate-in-prepubertal-children-with-growth-hormone-deficiency/ Wed, 29 Apr 2026 15:09:12 +0000 https://clinicaltrials.eu/trial/study-of-the-effects-of-ibutamoren-mesilate-in-prepubertal-children-with-growth-hormone-deficiency/ This study focuses on children who have not yet reached puberty and are experiencing Growth Hormone Deficiency. This condition occurs when the body does not produce enough of the natural hormone responsible for stimulating growth and development. The purpose of the study is to evaluate the effect of a daily oral medication called LUM 201 on growth rates over a period of 12 months.

Participants in the study will be assigned to receive either LUM 201 in the form of a capsule or a placebo. During the 12-month period, the study will monitor changes in growth and levels of specific substances in the blood, such as IGF-1, which is a hormone that helps the body grow, and IGFBP-3, a protein that carries these growth hormones through the bloodstream. Height and growth patterns will also be tracked throughout the course of the study.

]]>